대표이사 선임
파론 제약 오이
("Faron 또는 "회사")
대표이사 선임
Company announcement, April 8, 2024 at 9:00 (EEST) / 7:00 AM (BST) / 2:00 AM (EDT)
핀란드 투르쿠 / 매사추세츠주 보스턴 - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces that its Chief Executive Officer (CEO) Dr. Markku Jalkanen, who turns 70 later in 2024, has informed the Board of Directors of his wish to retire from his position as the Company's CEO during the course of Q2 2024, while continuing in his role as Board Member.
As a part of its ordinary tasks and noting the age of the current CEO, the Nomination Committee of the Board has maintained preparedness for CEO succession with the help of a third-party recruitment specialist firm, and considered several options for a potential new CEO for the Company among external and internal candidates. Supported by the preparatory work conducted, the Nomination Committee has concluded that the Company's current Chief Operating Officer, Dr. Juho Jalkanen, MD, PhD, MSc (economics), would be the best candidate to succeed Dr. Markku Jalkanen as CEO of the Company. Following information from Dr. Markku Jalkanen and the Nomination Committee's recommendation, the Board has resolved to appoint Dr. Juho Jalkanen as CEO of the Company, effective May 1, 2024, subject to regulatory approval. Dr. Markku Jalkanen will continue as a Board Member and support in the transition of the CEO role throughout 2024.
"I am very happy that the AGM approved the proposals by the Board of Directors, creating an opportunity for the Company to continue efforts on fundraising for a longer-term solution. I have worked for the Company since its inception in 2006 and feel that now is the right time for me to retire as CEO of the Company and leave the operative helm," said Dr. Markku Jalkanen, Chief Executive Officer of the Company. "The Board and I have a plan for a seamless CEO transition and now is the time to make that move. I will continue to give my support to the Company and the new CEO in my continuing role as Board Member. I also strongly believe in the promise of 벡스마리리맙 to provide a new safe and effective cancer treatment option for a vast patient group, either as a stand-alone or combination therapy."
"I am extremely honored that the Board has expressed its confidence in me as I assume the new challenge of CEO. I have enjoyed leading the development of 벡스마리리맙 as COO and look forward to the exciting future ahead of us as I continue to work relentlessly with the Faron team to deliver results for patients and shareholders. I want to thank Markku for his leadership and mentorship as CEO," said Dr. Juho Jalkanen, the incoming CEO.
자세한 내용은 다음으로 문의하십시오.
파론 제약
투자자 연락처
LifeSci Advisor
다니엘 페리
Managing Director
+1 (617) 430-7576
ICR 콘실리움
메리 제인 엘리엇, 데이빗 데일리, 린지 네빌
전화 : + 44 (0) 20 3709 5700
이메일: [이메일 보호]
Cairn Financial Advisers LLP, 노매드
샌디 제이미슨, 조 터너
전화번호: + 44 (0) 207 213 0880
껍질 사냥 LLP, Broker
크리스토퍼 골든, 제임스 스틸
전화번호: + 44 (0) 20 7418 8900
Sisu Partners Oy, Nasdaq First North의 공인 고문
주하 카르투넨
전화 : + 358 (0) 40 555 4727
유카 야르벨라
전화 : + 358 (0) 50 553 8990
Faron Pharmaceuticals Oy 소개
Faron(AIM: FARN, First North: FARON)은 새로운 면역요법을 통해 암을 치료하는 데 주력하는 글로벌 임상 단계 바이오제약 회사입니다. 그것의 임무는 면역 체계의 힘을 제어하고 활용하는 새로운 방법을 발견함으로써 더 많은 사람들에게 면역 요법의 가능성을 가져오는 것입니다. 회사의 납자산은 벡스마리리맙, 골수 세포 기능을 표적으로 하여 암의 면역 억제를 제거할 수 있는 잠재력을 가진 새로운 항-Clever-1 인간화 항체. 벡스마리리맙 is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.